VivoSeq
Oncology

Solid Malignancies

1

Pipeline Programs↗

9

Active Trials↗

11

Companies Involved↗

Solid Malignancies is an early-stage landscape with 1 program across 11 companies. The most active players are Eisai, Innovent Biologics (Suzhou) Co. Ltd., Arno Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

PreclinicalA

Arno Therapeutics

0 programs

PreclinicalK

Karyopharm Therapeutics Inc

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

IM-1021

Immunome, Inc.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

35

clinical trials

Completed17 · 49%
Recruiting6 · 17%
Terminated5 · 14%
Withdrawn3 · 9%
Active, not recruiting3 · 9%
Unknown status1 · 3%

Clinical Trials

Trial Activity

35 trials

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT07098299·60 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT05123482·460 enrolled
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Recruiting·CCarrick Therapeutics Limited·Phase 1/2·NCT06600789·50 enrolled
Retifanlimab and Ruxolitinib In Solid Malignancies
Recruiting·UUniversity of California, San Diego·Phase 1/2·NCT07219576·40 enrolled
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Recruiting·IImmunome, Inc.·Phase 1·NCT06823167·117 enrolled
Theranostic PET for Target Validation and Tumor Detection
Recruiting·UUniversity Hospital, Essen·N/A·NCT07664410·2,000 enrolled
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT01364051·19 enrolled
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Active, not recruiting·CCanadian Cancer Trials Group·Phase 1·NCT02537418·153 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Active, not recruiting·Gilead logoGilead·Phase 1·NCT05006794·145 enrolled
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03568539·39 enrolled
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT05866354·19 enrolled
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
Completed·RR-Pharm·Phase 1·NCT00162136·35 enrolled
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Completed·—·Phase 1·NCT03831295·12 enrolled
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
Completed·NNational University Hospital, Singapore·Phase 1·NCT04850755·11 enrolled
An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
Completed·Eisai logoEisai·Phase 1·NCT00121732·39 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)